BioHarvest Sciences (BHST) AI Stock Analysis

• Market Cap: $139.70M
• Dividend Yield: N/A
• Average Volume (3M): 109.63K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.45
• Revenue Growth: 45.88%
• EPS Growth: 43.12%
• Country: US
• Employees: 87
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Agricultural Inputs
• EPS (TTM): -0.14
• Shares Outstanding: 19,593,267
• 10 Day Avg. Volume: 113,678
• 30 Day Avg. Volume: 109,634
• PEG Ratio: 0.55
• Price to Book (P/B): 75.25
• Price to Sales (P/S): 3.97
• P/FCF Ratio: -10.51
• Enterprise Value/Market Cap: 0.97
• Enterprise Value/Revenue: 4.14
• Enterprise Value/Gross Profit: 7.00
• Enterprise Value/Ebitda: -29.41
• 1Y Price Target: $14.50
• Price Target Upside: 28.55% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: $6.50 ▼(-42.38% Downside)

BioHarvest Sciences faces significant challenges with profitability and financial stability, reflected in a low financial performance score. The technical analysis indicates a bearish trend, and the valuation is unattractive due to negative earnings. While the earnings call provided some positive insights, the overall outlook remains cautious.

Positive Factors

Revenue Growth

Sustained revenue growth reflects strong market demand and successful product adoption, indicating potential for long-term expansion.

Strategic Partnerships

The partnership with Saffron Tech enhances product offerings and market reach, leveraging innovative technology for sustainable growth.

Gross Profit Margin Improvement

Improved gross margins indicate efficient production processes and scalability, enhancing profitability potential over time.

Negative Factors

Financial Instability

Financial instability due to high leverage and negative equity poses risks to long-term sustainability and operational flexibility.

Net Losses

Ongoing net losses highlight challenges in achieving profitability, which could impact future investment and growth opportunities.

Increased Operating Expenses

Rising operating expenses may pressure margins and hinder profitability, requiring careful cost management to sustain growth.

BioHarvest Sciences Business Overview & Revenue Model

Company Description

BioHarvest Sciences (BHST) is a biotechnology company focused on the development and commercialization of innovative plant-based products, primarily in the health and wellness sectors. The company utilizes its proprietary BioHarvest technology to cultivate high-value plant cell cultures that produce bioactive compounds and nutraceuticals. Its core products include specialized compounds for dietary supplements, cosmetics, and functional foods, aimed at improving health outcomes and enhancing consumer wellness.

How the Company Makes Money

BioHarvest Sciences generates revenue through the sale of its plant-based products and compounds to various sectors, including dietary supplements and cosmetics. The company leverages its proprietary technology to create high-quality, scalable products that meet the growing demand for natural and sustainable health solutions. Key revenue streams include direct sales to manufacturers and retailers, licensing agreements for its technology, and potential partnerships with larger firms in the health and wellness industry. Additionally, BioHarvest may benefit from strategic collaborations and joint ventures that enhance its market reach and product offerings.

BioHarvest Sciences Financial Statement Overview

Summary

BioHarvest Sciences shows revenue growth and some cash flow improvement, but struggles with profitability and financial stability. High leverage and negative returns on equity highlight potential risks.

Income Statement

BioHarvest Sciences shows a positive revenue growth rate of 8.38% in the TTM, indicating an upward trend in sales. However, the company struggles with profitability, as evidenced by negative net profit and EBIT margins. The gross profit margin is relatively healthy at 59.21%, suggesting efficient production, but overall profitability remains a concern due to high operating expenses.

Balance Sheet

The company has a high debt-to-equity ratio of 2.57, indicating significant leverage, which poses a financial risk. The return on equity is negative, reflecting ongoing losses and a weak ability to generate returns for shareholders. The equity ratio is low, suggesting limited financial stability and a heavy reliance on debt financing.

Cash Flow

BioHarvest Sciences has a positive free cash flow growth rate of 2.94%, showing improvement in cash generation. However, the operating cash flow is negative, and the operating cash flow to net income ratio is below 1, indicating challenges in converting earnings into cash. The free cash flow to net income ratio is above 1, suggesting some efficiency in managing cash relative to net losses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	32.72M	25.19M	12.67M	5.50M	2.10M	396.00K
Gross Profit	19.37M	13.94M	5.63M	1.22M	670.00K	138.00K
EBITDA	-4.61M	-9.72M	-9.76M	-9.13M	-8.64M	-5.77M
Net Income	-11.89M	-12.91M	-12.56M	-11.24M	-9.83M	-6.58M
Balance Sheet
Total Assets	35.19M	25.00M	15.00M	9.39M	10.21M	5.30M
Cash, Cash Equivalents and Short-Term Investments	10.97M	2.39M	5.36M	1.74M	4.12M	1.78M
Total Debt	19.84M	13.82M	22.34M	10.56M	2.66M	2.71M
Total Liabilities	27.45M	23.67M	29.86M	15.32M	7.35M	7.60M
Stockholders Equity	7.74M	1.33M	-14.85M	-5.93M	2.85M	-2.29M
Cash Flow
Free Cash Flow	-10.07M	-9.52M	-10.00M	-10.50M	-8.43M	-4.05M
Operating Cash Flow	-8.00M	-6.68M	-8.52M	-9.24M	-6.79M	-3.88M
Investing Cash Flow	-2.07M	-3.03M	-1.47M	-1.26M	-1.64M	-173.00K
Financing Cash Flow	18.49M	6.78M	13.56M	8.14M	10.77M	4.93M

BioHarvest Sciences Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 11.28
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BHST, the sentiment is Negative. The current price of 11.28 is above the 20-day moving average (MA) of 8.26, above the 50-day MA of 9.62, and above the 200-day MA of 7.46, indicating a bearish trend. The MACD of -1.01 indicates Positive momentum. The RSI at 33.41 is Neutral, neither overbought nor oversold. The STOCH value of 15.68 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BHST.

BioHarvest Sciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IH	68 Neutral	$135.04M	9.28	11.71%	2.95%	-8.09%	-15.28%
Sector *	62 Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
AGEN	45 Neutral	$142.84M	―	―	―	-33.41%	81.19%
PRE	42 Neutral	$179.28M	―	-23.93%	―	159.45%	8.59%
BHST	41 Neutral	$139.70M	―	-200.22%	―	45.88%	43.12%
SGMO	39 Underperform	$131.94M	―	-480.02%	―	-37.13%	40.47%
HURA	36 Underperform	$127.76M	-0.70	-418.06%	―	―	99.21%

BioHarvest Sciences Corporate Events

BioHarvest Sciences Reports Strong Financial Position in Q3 2025

BioHarvest Sciences Inc. has released its unaudited interim condensed consolidated financial statements for the three and nine months ended September 30, 2025. The financial report highlights a significant increase in cash and cash equivalents from $2,390,000 at the end of 2024 to $10,966,000 as of September 30, 2025, indicating improved liquidity. This financial performance reflects the company’s ongoing efforts to strengthen its financial position, which could enhance its competitive edge in the biotechnology sector.

BioHarvest Sciences Partners with Saffron Tech for Saffron Compound Development

On October 30, 2025, BioHarvest Sciences announced a strategic CDMO agreement with Saffron Tech Ltd., aimed at developing and commercializing saffron-derived botanical compounds. This collaboration leverages BioHarvest’s Botanical Synthesis platform and Saffron Tech’s advanced cultivation methods to produce saffron compounds more sustainably and efficiently. The agreement grants Saffron Tech a 75% ownership of the developed compositions, while BioHarvest retains 25%. This partnership is expected to revolutionize saffron production by transitioning from traditional field-based cultivation to a controlled, cell-based process, addressing global supply challenges and expanding BioHarvest’s product offerings in the nutraceutical market.

BioHarvest Sciences Partners with Saffron Tech to Transform Saffron Production

On October 30, 2025, BioHarvest Sciences announced a strategic partnership with Saffron Tech to develop and commercialize saffron-derived botanical compounds using BioHarvest’s Botanical Synthesis platform. This collaboration aims to revolutionize saffron production by enabling consistent, scalable, and cost-effective production, addressing the challenges of traditional saffron cultivation. The partnership will allow BioHarvest to leverage its technology for large-scale manufacturing and marketing of saffron-based nutraceutical products. Additionally, BioHarvest shared its preliminary third-quarter 2025 results, with expected revenue of approximately $9.1 million and provided guidance for the fourth quarter, highlighting growth in its VINIA® business and CDMO services.

BioHarvest Sciences Fortifies Financial Position with $10.9 Million Warrant Exercises and Debt Conversions

On September 22, 2025, BioHarvest Sciences Inc. announced a successful series of financial transactions, including $10.9 million in warrant exercises and $3.8 million in debt conversions. These actions were aimed at strengthening the company’s financial position by reducing debt and increasing cash reserves. The transactions involved raising $5.8 million through warrant exercises, $5.1 million from new convertible notes, and converting $1.8 million of existing notes into shares. Additionally, $1.4 million of long-term debt was repaid through warrant exercises, and $0.6 million of short-term debt was settled by issuing shares. The proceeds will support capital expenditures, debt refinancing, and general working capital, positioning the company for continued growth.

BioHarvest Sciences Unveils Breakthrough in Plant-Based Exosome Production

On September 10, 2025, BioHarvest Sciences announced a significant breakthrough in its Botanical Synthesis technology by successfully producing plant-based exosomes at scale in its bioreactors. This advancement not only enhances the company’s proprietary platform but also opens new revenue streams in the cosmetics, health, and pharmaceutical industries. The plant-based exosomes, enriched with viniferin, offer superior absorption and bioavailability, making them highly desirable for therapeutic and cosmetic applications. This development positions BioHarvest as a key player in the growing exosome market, which is expected to expand significantly by 2030.

BioHarvest Sciences Files Shelf Registration for $100M Offering

On September 8, 2025, BioHarvest Sciences Inc. announced the filing and effectiveness of a shelf registration statement on Form F-3 with the U.S. Securities and Exchange Commission. This registration allows the company to offer and sell up to USD $100 million of its securities, including common shares, warrants, and units, subject to market conditions and the company’s capital needs. This strategic move positions BioHarvest to potentially enhance its financial flexibility and market presence, although it does not obligate the company to sell any specific amount of securities.

BioHarvest Sciences’ Shelf Registration Statement Goes Effective

On September 8, 2025, BioHarvest Sciences Inc. announced the effectiveness of its shelf registration statement on Form F-3 with the SEC, allowing the company to offer and sell up to USD $100 million of its securities, including common shares, warrants, and units. This strategic move provides BioHarvest with flexibility to raise capital as needed, subject to market conditions and SEC regulations, potentially strengthening its financial position and supporting its growth initiatives.